Interview with Dr. Rajesh Jain, Joint Managing Director, Panacea Biotec
The Indian biotechnology sector is quite particular. In spite of its young age, the industry has grown significantly in a very short time. In your view, where does the Indian…
Address: B-1 Extn./ A-27, Mohan Co-op. Industrial Estate, Mathura Road, New Delhi -110044, INDIA
,India
Tel: +91-11-26945270
Web: http://www.panaceabiotec.com/
Panacea Biotec is one of India’s leading research-based health management companies with established research, manufacturing and marketing capabilities. Panacea Biotec is the 2nd largest vaccine producer in India. Panacea Biotec has been ranked as the 3rd largest biotechnology company (ABLE Survey- June 2009) and is also amongst the top 50 pharmaceutical companies in India. The company has collaborations and tie-ups with leading national and international research organizations and corporations. The company’s state of the art manufacturing facilities for vaccines and pharmaceutical formulations comply with International Regulatory requirements like US-FDA, UK-MHRA, SAMCC and WHO-cGMP standards. Panacea Biotec has five dedicated research and development centers. The company has around 3200 employees including over 300 scientists. The company also has 24 product patents, valid in more than 60 countries worldwide.
The product portfolio of the Company includes highly innovative prescription products in important therapeutic areas such as pain management, diabetes management, renal-disease management, anti-osteoporosis, anti-tubercular, gastro-intestinal care products and vaccines.
The Indian biotechnology sector is quite particular. In spite of its young age, the industry has grown significantly in a very short time. In your view, where does the Indian…
KV Subramaniam, president of Reliance Life Sciences, a research-driven medical biotech with a fully integrated value chain that covers everything from research to manufacturing, comments on the firm’s unique positioning…
Suresh Pattathil wears two hats within India’s vast pharma ecosystem. Not only is he responsible for managing AbbVie India as its Managing Director and GM, he also advocates for broader…
In the latest blow to Indian pharma’s reputation, the European Medicines Agency (EMA) has recommended the suspension of marketing authorisations for a large number of generics tested by Indian CRO…
Director of the oldest and largest cancer centre in India, the Tata Memorial Hospital, C S Pramesh also heads up the National Cancer Grid (NCG), a nationwide network of over…
Over the course of his 40-year career, oncologist Dr Ramakant Deshpande has taken an active role in the evolution of cancer care in India and in 2017 he became the…
Ayushman Bharat, launched in 2018, is a monumental scheme addressing the lack of healthcare accessibility and affordability for over 500 million people in India. Dr Indu Bhushan, Ayushman Bharat’s inaugural…
India’s chemical industry is of vital importance to several industries, including pharmaceuticals, and exported USD 30.18 billion worth of products in 2022-23. Chemexcil’s Raghuveer Kini discusses his industry’s key role…
Pratima Reddy, GM at Merck Healthcare India reviews the importance of Merck’s Indian affiliate, discusses the recent reforms that have contributed both to improving patient access and to fostering foreign…
The Indian pharma industry has demonstrated spectacular growth based on its strength as a global generics manufacturer. Yet Indian pharma is not merely resting on its laurels. After shining through…
Sandeep Verma shares his journey of establishing Bayer’s consumer healthcare division in India and reflects on the challenges faced during the division’s inception amidst the COVID-19 pandemic, emphasizing the importance…
India’s pharma industry has big dreams. At the recent Annual Summit of Organisation of Pharmaceutical Producers of India (OPPI) the nation’s policymakers, academicians, industry leaders, innovators, and scientists gathered to…
Peter DeYoung shares the significance of Indian giant Piramal Pharma’s recent demerger from its parent company and its current strategic focus on organic growth, brownfield expansions, and “complex hospital generics.”…
See our Cookie Privacy Policy Here
